|
[1] WEI W,ZENG H,ZHENG R,et al. Cancer registration in China and its role in cancer prevention and control[J]. Lancet Oncol,2020,21(7):e342-e349.
|
|
[2] XIA Y,LI J,LIU G,et al. Long-term effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma:A randomized clinical trial[J]. JAMA Oncol,2019.[Online ahead of print]
|
|
[3] CHAN A,ZHANG WY,CHOK K,et al. ALPPS versus portal vein embolization for hepatitis-related hepatocellular carcinoma:A changing paradigm in modulation of future liver remnant before major hepatectomy[J]. Ann Surg,2019.[Online ahead of print]
|
|
[4] RAJYAGURU DJ,BORGERT AJ,SMITH AL,et al. Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients:Analysis of the national cancer database[J]. J Clin Oncol,2018,36(6):600-608.
|
|
[5] HARA K,TAKEDA A,TSURUGAI Y,et al. Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation:A propensity score analysis[J]. Hepatology,2019,69(6):2533-2545.
|
|
[6] KIM N,CHENG J,JUNG I,et al. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma[J]. J Hepatol,2020,73(1):121-129.
|
|
[7] WEI XB,JIANG YB,ZHANG XP,et al. Neoadjuvant threedimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus:A randomized,open-label,multicenter controlled study[J]. J Clin Oncol,2019,37(24):2141-2151.
|
|
[8] KUDO M,UESHIMA K,IKEDA M,et al. Randomised,multicentre prospective trial of transarterial chemoembolisation(TACE)plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma:TACTICS trial[J]. Gut,2020,69(8):1492-1501.
|
|
[9] HE MK,LI QJ,ZOU RH,et al. Sorafenib plus hepatic arterial infusion of oxaliplatin,fluorouracil,and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion:A randomized clinical trial[J]. JAMA Oncol,2019,5(7):953-960.
|
|
[10] MAI Q,MO Z,SHI F,et al. Lenvatinib plus hepatic arterial infusion of modified FOLFOX regime in patients with advanced hepatocellular carcinoma[J]. J Clin Oncol,2020,38(15_suppl):e16603.
|
|
[11] European Association for the Study of the Liver. EASL clinical practice guidelines:Management of hepatocellular carcinoma[J]. J Hepatol,2018,69(1):182-236.
|
|
[12] CHEN JH,LU L,WEN TF,et al. Adjuvant lenvatinib in combination with TACE for hepatocellular carcinoma patients with high risk of postoperative relapse(LANCE):Interim results from a muticenter prospective cohort study[J]. J Clin Oncol,2020,38(15_suppl):4580.
|
|
[13] BI F,QIN S,GU S,et al. Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma:An open-label,randomized,multicenter phase II/III trial[J]. J Clin Oncol,2020,38(15_suppl):4506.
|
|
[14] LI Q,QIN S,GU S,et al. Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma:A randomized,placebo-controlled,double-blind,phase III study[J]. J Clin Oncol,2020,38(15_suppl):4507.
|
|
[15] YAU T,PARK JW,FINN RS,et al. CheckMate 459:A randomized,multi-center phase III study of nivolumab(NIVO)vs sorafenib(SOR)as first-line(1L)treatment in patients(pts)with advanced hepatocellular carcinoma(a HCC)[J].Annals of Oncology,2019,30:874.
|
|
[16] FINN RS,RYOO BY,MERLE P,et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240:A randomized,double-blind,phase III trial[J]. J Clin Oncol,2019:JCO1901307.
|
|
[17] FINN RS,QIN S,IKEDA M,et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med,2020,382(20):1894-1905.
|
|
[18] ZHU AX,FINN RS,IKEDA M,et al. A phase Ib study of lenvatinib(LEN)plus pembrolizumab(PEMBRO)in unresectable hepatocellular carcinoma(u HCC)[J]. J Clin Oncol,2020,38(15_suppl):4519.
|
|
[19] KASEB AO,CAO HST,MOHAMED YI,et al. Final results of a randomized,open label,perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC[J]. J Clin Oncol,2020,38(15_suppl):4599.
|
|
[20] SUN HC,ZHU XD,HUANG C,et al. Initially unresectable hepatocellular carcinoma treated by combination therapy of tyrosine kinase inhibitor and anti-PD-1 antibody followed by resection[J]. J Clin Oncol,2020,38(15_suppl):e16690.
|
|
[21] TAI WMD,LOKE KSH,GOGNA A,et al. A phase II open-label,single-center,nonrandomized trial of Y90-radioembolization in combination with nivolumab in Asian patients with advanced hepatocellular carcinoma:CA 209-678[J]. J Clin Oncol,2020,38(15_suppl):4590.
|
|
[22] BROWN CE,MACKALL CL. CAR T cell therapy:Inroads to response and resistance[J]. Nat Rev Immunol,2019,19(2):73-74.
|
|
[23] MAUDE SL,LAETSCH TW,BUECHNER J,et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia[J]. N Engl J Med,2018,378(5):439-448.
|
|
[24] NEELAPU SS,LOCKE FL,BARTLETT NL,et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma[J]. N Engl J Med,2017,377(26):2531-2544.
|
|
[25] BO MD,MATTIA ED,BABOCI L,et al. New insights into the pharmacological,immunological,and CAR-T-cell approaches in the treatment of hepatocellular carcinoma[J]. Drug Resist Updat,2020,51:100702.
|
|
[26] GAO H,LI K,TU H,et al. Development of T cells redirected to Glypican-3 for the treatment of hepatocellular carcinoma[J]. Clin Cancer Res,2014,20(24):6418-6428.
|
|
[27] CHOI J,KIM HJ,LEE J,et al. Risk of hepatocellular carcinoma in patients treated with Entecavir vs Tenofovir for chronic hepatitis B:A Korean Nationwide cohort study[J]. JAMA Oncol,2019,5(1):30-36.
|
|
[28] CHOI J,JO C,LIM YS. Tenofovir vs. Entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection[J]. Hepatology,2020.[Online ahead of print]
|
DownLoad: